2,888 reports of this reaction
5.9% of all GALCANEZUMAB GNLM reports
#3 most reported adverse reaction
MIGRAINE is the #3 most commonly reported adverse reaction for GALCANEZUMAB GNLM, manufactured by Eli Lilly and Company. There are 2,888 FDA adverse event reports linking GALCANEZUMAB GNLM to MIGRAINE. This represents approximately 5.9% of all 49,086 adverse event reports for this drug.
Patients taking GALCANEZUMAB GNLM who experience migraine should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MIGRAINE is moderately reported among GALCANEZUMAB GNLM users, representing a notable but not dominant share of adverse events.
In addition to migraine, the following adverse reactions have been reported for GALCANEZUMAB GNLM:
The following drugs have also been linked to migraine in FDA adverse event reports:
MIGRAINE has been reported as an adverse event in 2,888 FDA reports for GALCANEZUMAB GNLM. This does not prove causation, but indicates an association observed in post-market surveillance data.
MIGRAINE accounts for approximately 5.9% of all adverse event reports for GALCANEZUMAB GNLM, making it one of the most commonly reported side effect.
If you experience migraine while taking GALCANEZUMAB GNLM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.